ПРОГНОЗИРОВАНИЕ ТРАНСФОРМАЦИИ РЕЦИДИВИРУЮЩЕЙ ФОРМЫ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ В ХРОНИЧЕСКУЮ У ПАЦИЕНТОВ С АРТЕРИАЛЬНОЙ ГИПЕРТОНИЕЙ

To evaluate the prognostic significance of markers of fibrosis in the risk of transition persistent atrial fibrillation in chronic form. It was revealed that the performance of remodeling of the left atrium (the level of PICP, TIMP-1, and the index of the PL to the BSA) have predictive value in the risk of progression of AF. The risk of transition to a chronic form of arrhythmia increases as the concentration of PICP over 133 ng/ml (Se 70–73% and Sp 62–75%), at a concentration of TIMP-1 less than 490 ng/ml (Se 67–78%, Sp 69–75%) and index of LP to PPT than 32–34 ml/m 2 (Se 80%, Sp 77–83%). For patients with AF against hypertension risk relapsing forms of transition to permanent AF occurs when the level of PICP over 151 ng/ml (1.01 fold increases in each of the subsequent increase in the concentration of 1 ng/ml) and the value of the index volume ma LP PPT to over 38 ml/m 2 (by 1.5 times for each subsequent increase of 1 ml/m2).

1. Аракелян М.С., Потешкина Н.Г., Могутова П.А. Современный взгляд на проблему фибрилляции предсердий и ее рецидивирования // Клиницист. 2011. № 3. С. 10–19.

2. Драпкина О.М. Фибрилляция предсердий и фиброз миокарда. Когда нужны статины? // Российские медицинские вести. 2012. Т. 17, № 2. С. 17–26.

3. Akdemir B., Altekin R., Küçük M. et al. The significance of the left atrial volume index in cardioversion success and its relationship with recurrence in patients with non-valvular atrial fibrillation subjected to electrical cardioversion: a study on diagnostic accuracy // Anadolu. Kardiyol. Derg. 2013. Vol. 13, № 1. P. 18–25.

4. Camm A., Kirchhof P., Lip G. et al. ESC Guidelines for the Management of Atrial Fibrillation (2010 Version) // Eur. Heart J. 2010. Vol. 6. P. 1–61.

5. López B., González A., Varo N. et al. Biochemical assessment of myocardial fibrosis in hypertensive heart disease // Hypertension. 2001. Vol. 38, № 5. P. 1222–1226.

6. Nguyen B., Fishbein M., Chen L. et al. Histopathological substrate for chronic atrial fibrillation in humans // Heart Rhythm. 2009. Vol. 6, № 4. P. 454–460.

7. Okumura Y., Watanabe I., Nakai T. et al. Impact of biomarkers of inflammation and extracellular matrix turnover on the outcome of atrial fibrillation ablation: importance of matrix metalloproteinase-2 as a predictor of atrial fibrillation recurrence // J. Cardiovasc. Electrophysiol. 2011. Vol. 22, № 9. P. 987–993.

8. Pinto A., Tuttolomondo A., Casuccio A. et al. Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation (NVAF) // Clin Sci (Lond). 2009. № 116.

9. Querejeta R., Lopez B., Gonzalez A. Increased collagen type I syntesis in patients with heart failure of hypertensive origin // Circulation. 2004. Vol. 110. P. 1263–1268.

10. Schnabel R. Can we predict the occurrence of atrial fibrillation // Clin. Cardiol. 2012. № 35, Suppl. 1. P. 5–9.